Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 3 of 14, showing 5 Applications out of 67 total, starting on record 11, ending on 15

# Protocol No Study Title Investigator(s) & Site(s)

11.

ECCT/23/09/04   GBT440-038Open-Label Extension
    An Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials       
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Videlis Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. Gertrude’s Children Hospital (Nairobi City county)
2. Kenya Medical Research Institute (KEMRI), Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI CRDR SIAYA within Siaya County Referral Hospital Grounds (Siaya county)
4. Strathmore University Medical Center, Centre for Research in Therapeutic Sciences (Nairobi City county)
 
View

12.

ECCT/23/10/04   ACCEDE OR Study
    Use of Continuous glucose monitoring devices among Type 1 diabetes patients followed up in CDiC clinics in Machakos, Nairobi and Kiambu counties in Kenya: A three-arm pragmatic study on effectiveness, feasibility, acceptability, and cost   
Principal Investigator(s)
1. Daniel Katambo Kiningu
Site(s) in Kenya
1. Machakos Level 5 Hospital (Machakos county)
2. Thika Level 5 Hospital (Kiambu county)
3. Kenya Diabetes Management and Information Centre (Machakos county)
 
View

13.

ECCT/23/09/03   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Simon Kariuki
Site(s) in Kenya
1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county)
 
View

14.

ECCT/23/04/01   mRNA-1273-P203
    A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age   
Principal Investigator(s)
1. Dr Janet Oyieko
Site(s) in Kenya
1. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county)
2. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county)
3. KEMRI/USAMRD (Kericho county)
4. Victoria Biomedical Research Institute (Kisumu county)
5. Kenya Medical Research Institute/USAMRU (Kisumu county)
6. KEMRI CMR-Kar Geno Research Centre (Kisumu county)
7. KEMRI/ CDC (Kisumu county)
8. KEMRI (Kisumu county)
9. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county)
 
View

15.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
View